Sartans Market Report Provides Insights Into Market Evolution And Growth Prospects

The sartans market is showing consistent progress, driven by ongoing demand for effective cardiovascular therapies worldwide. As healthcare dynamics evolve, this industry is set to maintain its upward trajectory, supported by both demographic shifts and technological advancements. Let's explore the current market landscape, key players, growth drivers, emerging trends, and significant segments influencing the sartans sector.

Current Market Size and Growth Projections for the Sartans Market
The sartans market has experienced steady growth over recent years, with its value rising from $22.18 billion in 2025 to an anticipated $23.09 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.1%. This expansion historically stems from the widespread prevalence of hypertension globally, the burden of cardiovascular diseases, a growing acceptance of generic medications, hospital prescribing practices, and the favorable long-term safety profile of sartans.

Download a free sample of the sartans market report:
https://thebusinessresearchcompany.com/sample_request?id=61596071&type=smp&name=Sartans%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Looking ahead, the market is expected to continue its steady climb, reaching $27.14 billion by 2030, again at a CAGR of 4.1%. Factors contributing to this growth include an aging population, increasing rates of kidney disease, the rising demand for affordable treatment options, expansion in outpatient care, and the growing role of digital pharmacies. Noteworthy trends anticipated during this period include heightened use of sartans for managing hypertension, greater adoption of generic angiotensin receptor blockers, preference for combination therapies in cardiovascular care, broader distribution through online pharmacies, and a stronger emphasis on renal and cardiovascular protection.

Key Companies Leading the Sartans Industry
The sartans market features numerous prominent players shaping its competitive environment. Leading companies in this space include Viatris Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Unichem Laboratories Ltd., Emcure Pharmaceuticals Ltd., Mylan N.V., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Abbott Laboratories, Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Bayer AG, and Merck & Co. Inc.

View the full sartans market report:
https://www.thebusinessresearchcompany.com/report/sartans-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

In a notable development from April 2025, Scienture Holdings, Inc., a US-based sartan manufacturer, collaborated with Saptalis Pharmaceuticals to produce Arbli, a losartan potassium oral suspension (10 mg/mL). This partnership also handles warehousing and distribution through strategic alliances to ensure readiness for the market launch of the first FDA-approved ready-to-use oral liquid losartan, aiming to meet unmet needs in hypertension therapy. Saptalis Pharmaceuticals is likewise a US-based firm, enhancing the domestic pharmaceutical landscape.

Emerging Trends Shaping the Sartans Market
Pharmaceutical companies in the sartans domain are increasingly concentrating on innovative formulations to improve treatment outcomes and patient compliance. One prominent example is the development of tablet-form sartans, which effectively block angiotensin II to relax blood vessels and lower blood pressure.

For instance, in July 2024, India-based Zydus Lifesciences secured FDA approval for its Valsartan Tablets USP available in 40 mg and 80 mg doses. Marketed under the brand name Diovan, these tablets are indicated for managing hypertension, heart failure, and enhancing survival after a heart attack in adults, with approval extended to pediatric patients aged one year and above.

Detailed Overview of Sartans Market Segments
This report segments the sartans market into several key categories to provide a comprehensive understanding:

1) By Product Type:
- Valsartan
- Telmisartan
- Losartan
- Irbesartan
- Azilsartan
- Olmesartan

2) By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Other Distribution Channels

3) By Application:
- Hypertension
- Cardiovascular Diseases
- Kidney Diseases
- Other Applications

4) By End-User:
- Hospitals
- Other End-Users

Subdivisions within product types further clarify the market composition. For example, Valsartan includes film-coated tablets, oral powder sachets, triple-combination tablets, and ready-to-use liquid formulations. Telmisartan covers soft gel capsules, mouth-dissolving strips, sustained-release tablets, and sachet-packed granules. Losartan varieties consist of chewable tablets, pediatric oral drops, effervescent tablets, and dispersible tablets. Irbesartan is available as high-potency tablets, scored tablets, hospital bulk packs, and blister strip packs. Azilsartan forms include nanoparticle-based tablets, rapid-onset tablets, unit-dose capsules, and microgranule sachets. Olmesartan products feature oral jelly formulations, oral thin films, powder-for-suspension packs, and dual-layer tablets.

Together, these segments reveal the extensive diversity and specialization within the sartans market, which continue to meet diverse patient needs and distribution preferences globally.

New analytical features added to our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.